\
&
Contact us
\
&
Contact us
Published on | 6 years ago
ProgrammesThe Committee of Senior Officials (CSO) has approved the funding for 4 COST Innovators Grants (CIG).
The COST Innovators Grant aims at enhancing the pace and success of breakthrough innovations, to build bridges between the scientific research performed in COST Actions and marketable applications and/or societal solutions and to explore innovation potential.
An overview of the approved COST Innovators Grants:
The full COST press release can be found here: https://www.cost.eu/news/cost-innovators-grant-4-applications-approved/
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
